Literature DB >> 19364659

Molecular characterization of IL-32 in human endothelial cells.

Hanako Kobayashi1, P Charles Lin.   

Abstract

IL-32 is a newly discovered protein found in human and certain primates, but absent in rodent. Various reports suggest its role as a proinflammatory mediator. Since vascular endothelium is critical in inflammation, we investigate IL-32 in endothelial cells. We found that the gene is expressed in human endothelial cells and Akt strongly induces its expression. Sequence analysis indicates IL-32 beta as the major isoform in endothelial cells. Surprisingly, we did not detect any secretion of IL-32 beta in human endothelial cells; instead we observed co-localization of IL-32 beta with endoplasmic reticulum, suggesting IL-32 beta is an intracellular protein in these cells. Promoter analysis identified a minimum required region for IL-32 transcription at -0.1 to +0.5 kb around the initially identified transcription start site. We also defined a transcriptional suppressor-binding site at -2.0 to -1.5 kb. Importantly, RNA ligase mediated rapid amplification of cDNA ends in endothelial cells determined the transcription start site at the 328 bp downstream from the original identified site. Finally, we found a positive correlation of IL-32 levels with human breast cancer and glioblastoma multiforme (GBM). These findings improve our understanding of IL-32 in vascular endothelium. IL-32 expression might be valuable as a biomarker for cancer.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19364659      PMCID: PMC2704890          DOI: 10.1016/j.cyto.2009.03.007

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  18 in total

Review 1.  Inflammation and necrosis promote tumour growth.

Authors:  Jukka Vakkila; Michael T Lotze
Journal:  Nat Rev Immunol       Date:  2004-08       Impact factor: 53.106

2.  Identification of a novel gene expressed in activated natural killer cells and T cells.

Authors:  C A Dahl; R P Schall; H L He; J S Cairns
Journal:  J Immunol       Date:  1992-01-15       Impact factor: 5.422

3.  Involvement of IL-32 in activation-induced cell death in T cells.

Authors:  Chiho Goda; Taisuke Kanaji; Sachiko Kanaji; Go Tanaka; Kazuhiko Arima; Shigeaki Ohno; Kenji Izuhara
Journal:  Int Immunol       Date:  2006-01-12       Impact factor: 4.823

4.  Association of genetic polymorphisms in the VEGF gene with breast cancer survival.

Authors:  Hua Lu; Xiao-Ou Shu; Yong Cui; Nobuhiko Kataoka; Wanqing Wen; Qiuyin Cai; Zhi-Xian Ruan; Yu-Tang Gao; Wei Zheng
Journal:  Cancer Res       Date:  2005-06-15       Impact factor: 12.701

5.  Interleukin-32: a cytokine and inducer of TNFalpha.

Authors:  Soo-Hyun Kim; Sun-Young Han; Tania Azam; Do-Young Yoon; Charles A Dinarello
Journal:  Immunity       Date:  2005-01       Impact factor: 31.745

6.  IL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanism.

Authors:  Mihai G Netea; Tania Azam; Gerben Ferwerda; Stephen E Girardin; Mark Walsh; Jong-Sung Park; Edward Abraham; Jin-Man Kim; Do-Young Yoon; Charles A Dinarello; Soo-Hyun Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-31       Impact factor: 11.205

7.  Epstein-barr virus-induced changes in B-lymphocyte gene expression.

Authors:  Kara L Carter; Ellen Cahir-McFarland; Elliott Kieff
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

8.  Interleukin-32, CCL2, PF4F1 and GFD10 are the only cytokine/chemokine genes differentially expressed by in vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes.

Authors:  Nicolas Cagnard; Franck Letourneur; Abdellatif Essabbani; Valérie Devauchelle; Sylvie Mistou; Audrey Rapinat; Charles Decraene; Catherine Fournier; Gilles Chiocchia
Journal:  Eur Cytokine Netw       Date:  2005-12       Impact factor: 2.737

9.  Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2.

Authors:  P Lin; J A Buxton; A Acheson; C Radziejewski; P C Maisonpierre; G D Yancopoulos; K M Channon; L P Hale; M W Dewhirst; S E George; K G Peters
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-21       Impact factor: 11.205

10.  Endogenous IL-32 controls cytokine and HIV-1 production.

Authors:  Marcel F Nold; Claudia A Nold-Petry; Gregory B Pott; Jarod A Zepp; Milene T Saavedra; Soo-Hyun Kim; Charles A Dinarello
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.426

View more
  22 in total

Review 1.  Neuroinflammation: a common pathway in CNS diseases as mediated at the blood-brain barrier.

Authors:  Michelle A Erickson; Kenji Dohi; William A Banks
Journal:  Neuroimmunomodulation       Date:  2012-01-11       Impact factor: 2.492

2.  Interleukin-32β stimulates migration of MDA-MB-231 and MCF-7cells via the VEGF-STAT3 signaling pathway.

Authors:  Jeong Su Park; Su Yun Choi; Jeong-Hyung Lee; Maria Lee; Eun Sook Nam; Ae Lee Jeong; Sunyi Lee; Sora Han; Myeong-Sok Lee; Jong-Seok Lim; Do Young Yoon; Yongil Kwon; Young Yang
Journal:  Cell Oncol (Dordr)       Date:  2013-10-10       Impact factor: 6.730

3.  Activation of the interleukin-32 pro-inflammatory pathway in response to human papillomavirus infection and over-expression of interleukin-32 controls the expression of the human papillomavirus oncogene.

Authors:  Sojung Lee; Jung-Hee Kim; Heejong Kim; Jeong Woo Kang; Soo-Hyun Kim; Young Yang; Jinman Kim; JongSup Park; SurNie Park; JinTae Hong; Do-Young Yoon
Journal:  Immunology       Date:  2011-01-05       Impact factor: 7.397

4.  IL-32 promotes angiogenesis.

Authors:  Claudia A Nold-Petry; Ina Rudloff; Yvonne Baumer; Menotti Ruvo; Daniela Marasco; Paolo Botti; Laszlo Farkas; Steven X Cho; Jarod A Zepp; Tania Azam; Hannah Dinkel; Brent E Palmer; William A Boisvert; Carlyne D Cool; Laima Taraseviciene-Stewart; Bas Heinhuis; Leo A B Joosten; Charles A Dinarello; Norbert F Voelkel; Marcel F Nold
Journal:  J Immunol       Date:  2013-12-11       Impact factor: 5.422

Review 5.  Aptamers Against Pro- and Anti-Inflammatory Cytokines: A Review.

Authors:  Maryam Boshtam; Seddigheh Asgary; Shirin Kouhpayeh; Laleh Shariati; Hossein Khanahmad
Journal:  Inflammation       Date:  2017-02       Impact factor: 4.092

6.  Role of interleukin-32 in Helicobacter pylori-induced gastric inflammation.

Authors:  Kosuke Sakitani; Yoshihiro Hirata; Yoku Hayakawa; Takako Serizawa; Wachiko Nakata; Ryota Takahashi; Hiroto Kinoshita; Kei Sakamoto; Hayato Nakagawa; Masao Akanuma; Haruhiko Yoshida; Shin Maeda; Kazuhiko Koike
Journal:  Infect Immun       Date:  2012-08-13       Impact factor: 3.441

7.  Interleukin-32beta propagates vascular inflammation and exacerbates sepsis in a mouse model.

Authors:  Hanako Kobayashi; Jianhua Huang; Fei Ye; Yu Shyr; Timothy S Blackwell; P Charles Lin
Journal:  PLoS One       Date:  2010-03-05       Impact factor: 3.240

8.  IL-32 expression is an independent prognostic marker for gastric cancer.

Authors:  Sumiya Ishigami; Takaaki Arigami; Yasuto Uchikado; Tetsuro Setoyama; Yoshiaki Kita; Ken Sasaki; Hiroshi Okumura; Hiroshi Kurahara; Yuko Kijima; Aya Harada; Shinichi Ueno; Shoji Natsugoe
Journal:  Med Oncol       Date:  2013-03-12       Impact factor: 3.064

9.  Intracellular interaction of interleukin (IL)-32α with protein kinase Cε (PKCε ) and STAT3 protein augments IL-6 production in THP-1 promonocytic cells.

Authors:  Jeong-Woo Kang; Yun Sun Park; Dong Hun Lee; Jung-Hee Kim; Man Sub Kim; Yesol Bak; Jintae Hong; Do-Young Yoon
Journal:  J Biol Chem       Date:  2012-08-27       Impact factor: 5.157

Review 10.  Novel insights into the biology of interleukin-32.

Authors:  Leo A B Joosten; Bas Heinhuis; Mihai G Netea; Charles A Dinarello
Journal:  Cell Mol Life Sci       Date:  2013-03-06       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.